BBX Logo Beta

Lite Strategy, Inc. (LITS)

Crypto Stocks
Lite Strategy, Inc.
Mon, 5/25/2026, 01:56:23 AM
logo
Lite Strategy, Inc.
NASDAQ · $LITS
Crypto Strategic Reserve
$1.075
--
Company Information
Lite Strategy, Inc. is a clinical-stage pharmaceutical company focused on developing various cancer therapies. The company is developing ME-344, an intravenous small molecule inhibitor of mitochondrial oxidative phosphorylation for the treatment of human epidermal growth factor receptor 2-negative breast cancer, colorectal cancer, and solid tumors. The company was founded in 2000 and is headquartered in San Diego, California. Recently, MEI Pharma, Inc. also announced the launch of a Litecoin treasury strategy, becoming the first and only publicly traded holder of LTC.
Coin Reserve Status
LTC
Long press to scan QR code for more content
Lite Strategy, Inc.

Lite Strategy, Inc.

$LITSNASDAQ
Crypto Strategic Reserve
Buy Token

Company Information

Lite Strategy, Inc. is a clinical-stage pharmaceutical company focused on developing various cancer therapies. The company is developing ME-344, an intravenous small molecule inhibitor of mitochondrial oxidative phosphorylation for the treatment of human epidermal growth factor receptor 2-negative breast cancer, colorectal cancer, and solid tumors. The company was founded in 2000 and is headquartered in San Diego, California. Recently, MEI Pharma, Inc. also announced the launch of a Litecoin treasury strategy, becoming the first and only publicly traded holder of LTC.
CEO
Mr. Justin J. File CPA
Founded
2000
Headquarters
9920 Pacific Heights Blvd., Suite 150, San Diego, CA 92121, United States
EXCHANGE
NASDAQ
H
Annual High
$1.65
L
Annual Low
$0.95
View Related Announcements

Stock Chart

Business Model

Business Mode

  • Business Model: MEI Pharma's business model is to discover, develop, and commercialize novel and differentiated therapies for the treatment of cancer. As a clinical-stage pharmaceutical company, its main activities include:
  • Drug Development: Focusing on the development of innovative cancer drugs targeting known resistance mechanisms.
  • Clinical Trials: Evaluating the safety, efficacy, and pharmacokinetics of drugs through clinical trials at different stages.
  • Collaboration and Licensing: Potentially accelerating development and commercialization by collaborating with large pharmaceutical companies or licensing its drug pipeline.
  • Digital Asset Strategy: Investing a portion of its funds in cryptocurrencies by launching a Litecoin reserve strategy, aiming for asset appreciation and diversification.

Profit Model

  • Profit Model: As a clinical-stage pharmaceutical company, MEI Pharma's profit model primarily relies on the success of its R&D drugs and subsequent commercialization, with the addition of cryptocurrency investment income:
    • Milestone Payments and Royalties: Payments are received through agreements with partners when drug development reaches specific milestones, and sales royalties are obtained after the drug is launched.
    • Product Sales: If its drugs receive regulatory approval and are successfully launched, revenue will be generated through direct sales or co-sales with partners.
    • Equity Financing: During the drug development phase, the company typically raises funds through methods such as issuing stock to support R&D investments.
    • Cryptocurrency Investment Income: By investing in cryptocurrencies like Litecoin, the aim is to achieve asset appreciation and financial diversification.

Impact on Cryptocurrencies

  • Litecoin Reserve Strategy: MEI Pharma has announced the launch of a $100 million private placement aimed at initiating a Litecoin treasury strategy and becoming the first and only publicly traded holder of LTC.
  • Main Held Cryptocurrency: Litecoin (LTC).
  • Strategic Purpose: By investing in Litecoin, the aim is to achieve long-term growth and maximize shareholder value, while providing additional financial flexibility for future operations.